210 related articles for article (PubMed ID: 28679327)
1. Micro factors bringing the pharmaceutical industry to a seismic shaking a qualitative research.
Dierks RML; Bruyère O; Reginster JY
Expert Rev Pharmacoecon Outcomes Res; 2017 Jun; 17(3):267-274. PubMed ID: 28679327
[TBL] [Abstract][Full Text] [Related]
2. Critical analysis of valuation and strategical orientation of merger and acquisition deals in the pharmaceutical industry.
Dierks RML; Bruyère O; Reginster JY
Expert Rev Pharmacoecon Outcomes Res; 2018 Apr; 18(2):147-160. PubMed ID: 29243501
[TBL] [Abstract][Full Text] [Related]
3. Macro-economic factors influencing the architectural business model shift in the pharmaceutical industry.
Dierks RM; Bruyère O; Reginster JY; Richy FF
Expert Rev Pharmacoecon Outcomes Res; 2016 Oct; 16(5):571-578. PubMed ID: 27653356
[TBL] [Abstract][Full Text] [Related]
4. Virtual pharmaceutical companies: collaborating flexibly in pharmaceutical development.
Forster SP; Stegmaier J; Spycher R; Seeger S
Drug Discov Today; 2014 Mar; 19(3):348-55. PubMed ID: 24291787
[TBL] [Abstract][Full Text] [Related]
5. Financial Times Global Pharmaceutical & Biotechnology Conference 2009.
Scattereggia J
IDrugs; 2010 Jan; 13(1):26-9. PubMed ID: 20024844
[TBL] [Abstract][Full Text] [Related]
6. Equipment and analytical companies meeting continuous challenges. May 20-21, 2014 Continuous Manufacturing Symposium.
Page T; Dubina H; Fillipi G; Guidat R; Patnaik S; Poechlauer P; Shering P; Guinn M; Mcdonnell P; Johnston C
J Pharm Sci; 2015 Mar; 104(3):821-31. PubMed ID: 25448273
[TBL] [Abstract][Full Text] [Related]
7. Research and development productivity map: visualization of industry status.
Shimura H; Masuda S; Kimura H
J Clin Pharm Ther; 2014 Apr; 39(2):175-80. PubMed ID: 24438433
[TBL] [Abstract][Full Text] [Related]
8. The impact of mergers on pharmaceutical R&D.
LaMattina JL
Nat Rev Drug Discov; 2011 Aug; 10(8):559-60. PubMed ID: 21804580
[TBL] [Abstract][Full Text] [Related]
9. Foundation-industry relationships--a new business model joint-venture philanthropy in therapy development.
Bartek RJ
Curr Top Med Chem; 2014; 14(3):313-8. PubMed ID: 24283968
[TBL] [Abstract][Full Text] [Related]
10. Discussion point: should governments buy drug patents?
del Llano J
Eur J Health Econ; 2007 Jun; 8(2):173-7. PubMed ID: 17225128
[TBL] [Abstract][Full Text] [Related]
11. Improving R&D productivity of pharmaceutical companies through public-private partnership: experiences from the Innovative Medicines Initiative.
Laverty H; Gunn M; Goldman M
Expert Rev Pharmacoecon Outcomes Res; 2012 Oct; 12(5):545-8. PubMed ID: 23136843
[No Abstract] [Full Text] [Related]
12. Strategic balance of drug lifecycle management options differs between domestic and foreign companies in Japan.
Yamanaka T; Kano S
Expert Opin Ther Pat; 2016; 26(4):497-503. PubMed ID: 26881292
[TBL] [Abstract][Full Text] [Related]
13. Mastering the value chain. An interview with Mark Levin of Millennium Pharmaceuticals. Interview by David Champion.
Levin M
Harv Bus Rev; 2001 Jun; 79(6):108-15, 148. PubMed ID: 11408971
[TBL] [Abstract][Full Text] [Related]
14. An unbalanced portfolio.
Federsel HJ
Drug News Perspect; 2009 Jun; 22(5):287-92. PubMed ID: 19609466
[TBL] [Abstract][Full Text] [Related]
15. Overcoming the challenges in the pharma/biotech industry.
Graul AI; Prous JR
Drug News Perspect; 2007; 20(1):57-68. PubMed ID: 17332900
[TBL] [Abstract][Full Text] [Related]
16. No immediate pain relief for the pharmaceutical industry.
Ahlborn H; Henderson S; Davies N
Curr Opin Drug Discov Devel; 2005 May; 8(3):384-91. PubMed ID: 15892254
[TBL] [Abstract][Full Text] [Related]
17. A lesson from Japan: research and development efficiency is a key element of pharmaceutical industry consolidation process.
Shimura H; Masuda S; Kimura H
Drug Discov Ther; 2014 Feb; 8(1):57-63. PubMed ID: 24647159
[TBL] [Abstract][Full Text] [Related]
18. Alcohol medications development: advantages and caveats of government/academia collaborating with the pharmaceutical industry.
Litten RZ; Ryan M; Falk D; Fertig J
Alcohol Clin Exp Res; 2014 May; 38(5):1196-9. PubMed ID: 24689461
[TBL] [Abstract][Full Text] [Related]
19. Drug discovery: new models for industry-academic partnerships.
Tralau-Stewart CJ; Wyatt CA; Kleyn DE; Ayad A
Drug Discov Today; 2009 Jan; 14(1-2):95-101. PubMed ID: 18992364
[TBL] [Abstract][Full Text] [Related]
20. Accessing external innovation in drug discovery and development.
Tufféry P
Expert Opin Drug Discov; 2015 Jun; 10(6):579-89. PubMed ID: 25910932
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
